Skip to Main Content
Table 1.

Quantification of the effect of morpholino-mediated depletion of Her6 and/or Her4

Percentage of embryos with visible intersomitic boundary abnormalities(n)
Time
MO Treatment20 hours48 hoursSomite number where boundary abnormalities start
her6 (3 ng, n=44) 14 (6) 75 (33) 22±0.5 
her6 (6 ng, n=46) 74 (34) 93 (43) 20±0.5 
her4 (3 ng, n=48) 2 (1) 29 (14) 25±0.6 
her4 (6 ng, n=45) 27 (12) 71 (32) 23±0.5 
her6 + her4 (3 + 3 ng, n=30) 76 (23) 100 (30) 11±1 
Percentage of embryos with visible intersomitic boundary abnormalities(n)
Time
MO Treatment20 hours48 hoursSomite number where boundary abnormalities start
her6 (3 ng, n=44) 14 (6) 75 (33) 22±0.5 
her6 (6 ng, n=46) 74 (34) 93 (43) 20±0.5 
her4 (3 ng, n=48) 2 (1) 29 (14) 25±0.6 
her4 (6 ng, n=45) 27 (12) 71 (32) 23±0.5 
her6 + her4 (3 + 3 ng, n=30) 76 (23) 100 (30) 11±1 

n indicates the total number of embryos analysed for each condition. Each batch of injected embryos was analysed at two different time points during development (20 hours and 48 hours). At 48 hours, the embryos were processed for immunohystochemistry with an anti-myosin heavy chain antibody and the number of normally formed somites was counted. A somite was considered normal if both the anterior and the posterior boundaries were complete. Numbers represent the mean±s.e.m.

Close Modal

or Create an Account

Close Modal
Close Modal